Theratechnologies regains U.S. marketing rights to Egrifta

Dec 13, 2013
PDF Version
Supporting Materials:

Theratechnologies Inc. (TSX: TH) today announced that it has reached an agreement with EMD Serono to regain all rights under the current collaboration and licensing agreement entered into in 2008 with EMD Serono, including commercialization rights for EGRIFTA® (tesamorelin for injection) in the United States.